Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis
Abstract Background The role of adjuvant radiotherapy (ART) after radical prostatectomy (RP) on survival of patients with prostate cancer (PCa) is still controversial. Objective We tested the impact of ART on cancer-specific mortality (CSM) and overall mortality (OM) in PCa patients according to pat...
Gespeichert in:
Veröffentlicht in: | European urology 2013-06, Vol.63 (6), p.998-1008 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1008 |
---|---|
container_issue | 6 |
container_start_page | 998 |
container_title | European urology |
container_volume | 63 |
creator | Abdollah, Firas Suardi, Nazareno Cozzarini, Cesare Gallina, Andrea Capitanio, Umberto Bianchi, Marco Sun, Maxine Fossati, Nicola Passoni, Niccolò Maria Fiorino, Claudio Di Muzio, Nadia Karakiewicz, Pierre I Rigatti, Patrizio Montorsi, Francesco Briganti, Alberto |
description | Abstract Background The role of adjuvant radiotherapy (ART) after radical prostatectomy (RP) on survival of patients with prostate cancer (PCa) is still controversial. Objective We tested the impact of ART on cancer-specific mortality (CSM) and overall mortality (OM) in PCa patients according to pathologic PCa features. Design, setting, and participants We evaluated 1049 PCa patients treated with RP and extended pelvic lymph node dissection alone or in combination with adjuvant treatments between 1998 and 2008. All patients had positive surgical margins and/or pT3/pT4 disease with or without positive lymph nodes. Outcome measurements and statistical analysis Cox regression analyses tested the relationship between pathologic characteristics and CSM rates. Independent predictors of survival were used to develop a novel risk score based on the number of risk factors. Finally, Cox regression models tested the relationship between ART and survival according to the number of risk factors. Results and limitations On multivariable analyses, only pathologic Gleason score ≥8, pT3b/T4 stage, and presence of positive lymph nodes represented independent predictors of CSM (all p ≤ 0.02). The cumulative number of these pathologic findings was used to develop a risk score, which was 0, 1, 2, and 3 in 43.6%, 22.1%, 20.7%, and 13.6% of patients, respectively. In patients sharing more than two mentioned predictors of CSM (primarily having a risk score of 0 or 1), ART did not significantly improve survival (all p ≥ 0.4). Conversely, in patients with a risk score ≥2, ART was associated with lower CSM and OM rates (all p = 0.006). The observational nature of the cohort represents a limitation of the study. Conclusions ART significantly improved survival only in patients with at least two of the following pathologic features at RP: Gleason score ≥8, pT3/pT4 disease, and positive lymph nodes. These patients represent the ideal candidates for ART after RP. |
doi_str_mv | 10.1016/j.eururo.2012.10.036 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1345513402</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0302283812012675</els_id><sourcerecordid>1345513402</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-78020b6d4fbf1dbf192b3b1536c3211b12885a077eff9745583f7fbed86142e43</originalsourceid><addsrcrecordid>eNqFUsuqFDEUDKJ4x6t_IJKN4KbHPPo1LoRm8AUDVxxdh3Tn5JqxuzMm6YH-Az_b03fmKrhxkQSKqkpOVQh5ztmaM16-PqxhClPwa8G4QGjNZPmArHhdyawqSvaQrJhkIhO1rK_IkxgPjDFZbORjciUkF6Is8xX5tYceuuTGW5q-A705Jjfonm71aJzRCaj1gTbmMJ30mOgXbZxHXtDHmTY2QbiDOlR8Dj4mFHTJD_Od6h5ZzDoIb2hDd368zVA10P0UTu6EumbU_RxdfEoeWd1HeHY5r8m39---bj9mu5sPn7bNLuvyvEpZVTPB2tLktrXc4NqIVra8kGUnBectF3VdaFZVYO2myouilrayLZi65LmAXF6TV2ffY_A_J4hJDS520Pd6BD9FxSWKcGMCqfmZ2uEkMYBVx4DphFlxppYO1EGdO1BLBwuKHaDsxeWGqR3A_BHdh46ElxeCjhidDZiPi395leSSbRjy3p55gHmcHAQVOweYpXEBc1bGu_-95F-DrnfjUtcPmCEe_BQwfZxZRaGY2i__ZfkufDEpq0L-BhOHvOA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1345513402</pqid></control><display><type>article</type><title>Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Abdollah, Firas ; Suardi, Nazareno ; Cozzarini, Cesare ; Gallina, Andrea ; Capitanio, Umberto ; Bianchi, Marco ; Sun, Maxine ; Fossati, Nicola ; Passoni, Niccolò Maria ; Fiorino, Claudio ; Di Muzio, Nadia ; Karakiewicz, Pierre I ; Rigatti, Patrizio ; Montorsi, Francesco ; Briganti, Alberto</creator><creatorcontrib>Abdollah, Firas ; Suardi, Nazareno ; Cozzarini, Cesare ; Gallina, Andrea ; Capitanio, Umberto ; Bianchi, Marco ; Sun, Maxine ; Fossati, Nicola ; Passoni, Niccolò Maria ; Fiorino, Claudio ; Di Muzio, Nadia ; Karakiewicz, Pierre I ; Rigatti, Patrizio ; Montorsi, Francesco ; Briganti, Alberto</creatorcontrib><description>Abstract Background The role of adjuvant radiotherapy (ART) after radical prostatectomy (RP) on survival of patients with prostate cancer (PCa) is still controversial. Objective We tested the impact of ART on cancer-specific mortality (CSM) and overall mortality (OM) in PCa patients according to pathologic PCa features. Design, setting, and participants We evaluated 1049 PCa patients treated with RP and extended pelvic lymph node dissection alone or in combination with adjuvant treatments between 1998 and 2008. All patients had positive surgical margins and/or pT3/pT4 disease with or without positive lymph nodes. Outcome measurements and statistical analysis Cox regression analyses tested the relationship between pathologic characteristics and CSM rates. Independent predictors of survival were used to develop a novel risk score based on the number of risk factors. Finally, Cox regression models tested the relationship between ART and survival according to the number of risk factors. Results and limitations On multivariable analyses, only pathologic Gleason score ≥8, pT3b/T4 stage, and presence of positive lymph nodes represented independent predictors of CSM (all p ≤ 0.02). The cumulative number of these pathologic findings was used to develop a risk score, which was 0, 1, 2, and 3 in 43.6%, 22.1%, 20.7%, and 13.6% of patients, respectively. In patients sharing more than two mentioned predictors of CSM (primarily having a risk score of 0 or 1), ART did not significantly improve survival (all p ≥ 0.4). Conversely, in patients with a risk score ≥2, ART was associated with lower CSM and OM rates (all p = 0.006). The observational nature of the cohort represents a limitation of the study. Conclusions ART significantly improved survival only in patients with at least two of the following pathologic features at RP: Gleason score ≥8, pT3/pT4 disease, and positive lymph nodes. These patients represent the ideal candidates for ART after RP.</description><identifier>ISSN: 0302-2838</identifier><identifier>EISSN: 1873-7560</identifier><identifier>DOI: 10.1016/j.eururo.2012.10.036</identifier><identifier>PMID: 23122664</identifier><identifier>CODEN: EUURAV</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Adjuvant ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Cohort Studies ; Combined Modality Therapy ; Disease-Free Survival ; Gynecology. Andrology. Obstetrics ; Humans ; Lymph Node Excision ; Male ; Male genital diseases ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Neoplasm Grading ; Neoplasm recurrence ; Neoplasm Staging ; Nephrology. Urinary tract diseases ; Patient Selection ; Pelvis ; Proportional Hazards Models ; Prostatectomy ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - therapy ; Prostatic neoplasms/surgery ; Radiotherapy ; Radiotherapy, Adjuvant ; Retrospective Studies ; Risk Assessment ; Risk factors ; Survival Analysis ; Treatment Outcome ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland ; Urology</subject><ispartof>European urology, 2013-06, Vol.63 (6), p.998-1008</ispartof><rights>European Association of Urology</rights><rights>2012 European Association of Urology</rights><rights>2014 INIST-CNRS</rights><rights>Copyright © 2012 European Association of Urology. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-78020b6d4fbf1dbf192b3b1536c3211b12885a077eff9745583f7fbed86142e43</citedby><cites>FETCH-LOGICAL-c447t-78020b6d4fbf1dbf192b3b1536c3211b12885a077eff9745583f7fbed86142e43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.eururo.2012.10.036$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27313090$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23122664$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abdollah, Firas</creatorcontrib><creatorcontrib>Suardi, Nazareno</creatorcontrib><creatorcontrib>Cozzarini, Cesare</creatorcontrib><creatorcontrib>Gallina, Andrea</creatorcontrib><creatorcontrib>Capitanio, Umberto</creatorcontrib><creatorcontrib>Bianchi, Marco</creatorcontrib><creatorcontrib>Sun, Maxine</creatorcontrib><creatorcontrib>Fossati, Nicola</creatorcontrib><creatorcontrib>Passoni, Niccolò Maria</creatorcontrib><creatorcontrib>Fiorino, Claudio</creatorcontrib><creatorcontrib>Di Muzio, Nadia</creatorcontrib><creatorcontrib>Karakiewicz, Pierre I</creatorcontrib><creatorcontrib>Rigatti, Patrizio</creatorcontrib><creatorcontrib>Montorsi, Francesco</creatorcontrib><creatorcontrib>Briganti, Alberto</creatorcontrib><title>Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis</title><title>European urology</title><addtitle>Eur Urol</addtitle><description>Abstract Background The role of adjuvant radiotherapy (ART) after radical prostatectomy (RP) on survival of patients with prostate cancer (PCa) is still controversial. Objective We tested the impact of ART on cancer-specific mortality (CSM) and overall mortality (OM) in PCa patients according to pathologic PCa features. Design, setting, and participants We evaluated 1049 PCa patients treated with RP and extended pelvic lymph node dissection alone or in combination with adjuvant treatments between 1998 and 2008. All patients had positive surgical margins and/or pT3/pT4 disease with or without positive lymph nodes. Outcome measurements and statistical analysis Cox regression analyses tested the relationship between pathologic characteristics and CSM rates. Independent predictors of survival were used to develop a novel risk score based on the number of risk factors. Finally, Cox regression models tested the relationship between ART and survival according to the number of risk factors. Results and limitations On multivariable analyses, only pathologic Gleason score ≥8, pT3b/T4 stage, and presence of positive lymph nodes represented independent predictors of CSM (all p ≤ 0.02). The cumulative number of these pathologic findings was used to develop a risk score, which was 0, 1, 2, and 3 in 43.6%, 22.1%, 20.7%, and 13.6% of patients, respectively. In patients sharing more than two mentioned predictors of CSM (primarily having a risk score of 0 or 1), ART did not significantly improve survival (all p ≥ 0.4). Conversely, in patients with a risk score ≥2, ART was associated with lower CSM and OM rates (all p = 0.006). The observational nature of the cohort represents a limitation of the study. Conclusions ART significantly improved survival only in patients with at least two of the following pathologic features at RP: Gleason score ≥8, pT3/pT4 disease, and positive lymph nodes. These patients represent the ideal candidates for ART after RP.</description><subject>Adjuvant</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Cohort Studies</subject><subject>Combined Modality Therapy</subject><subject>Disease-Free Survival</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Lymph Node Excision</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Grading</subject><subject>Neoplasm recurrence</subject><subject>Neoplasm Staging</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Patient Selection</subject><subject>Pelvis</subject><subject>Proportional Hazards Models</subject><subject>Prostatectomy</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Prostatic neoplasms/surgery</subject><subject>Radiotherapy</subject><subject>Radiotherapy, Adjuvant</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Risk factors</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><subject>Urology</subject><issn>0302-2838</issn><issn>1873-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUsuqFDEUDKJ4x6t_IJKN4KbHPPo1LoRm8AUDVxxdh3Tn5JqxuzMm6YH-Az_b03fmKrhxkQSKqkpOVQh5ztmaM16-PqxhClPwa8G4QGjNZPmArHhdyawqSvaQrJhkIhO1rK_IkxgPjDFZbORjciUkF6Is8xX5tYceuuTGW5q-A705Jjfonm71aJzRCaj1gTbmMJ30mOgXbZxHXtDHmTY2QbiDOlR8Dj4mFHTJD_Od6h5ZzDoIb2hDd368zVA10P0UTu6EumbU_RxdfEoeWd1HeHY5r8m39---bj9mu5sPn7bNLuvyvEpZVTPB2tLktrXc4NqIVra8kGUnBectF3VdaFZVYO2myouilrayLZi65LmAXF6TV2ffY_A_J4hJDS520Pd6BD9FxSWKcGMCqfmZ2uEkMYBVx4DphFlxppYO1EGdO1BLBwuKHaDsxeWGqR3A_BHdh46ElxeCjhidDZiPi395leSSbRjy3p55gHmcHAQVOweYpXEBc1bGu_-95F-DrnfjUtcPmCEe_BQwfZxZRaGY2i__ZfkufDEpq0L-BhOHvOA</recordid><startdate>20130601</startdate><enddate>20130601</enddate><creator>Abdollah, Firas</creator><creator>Suardi, Nazareno</creator><creator>Cozzarini, Cesare</creator><creator>Gallina, Andrea</creator><creator>Capitanio, Umberto</creator><creator>Bianchi, Marco</creator><creator>Sun, Maxine</creator><creator>Fossati, Nicola</creator><creator>Passoni, Niccolò Maria</creator><creator>Fiorino, Claudio</creator><creator>Di Muzio, Nadia</creator><creator>Karakiewicz, Pierre I</creator><creator>Rigatti, Patrizio</creator><creator>Montorsi, Francesco</creator><creator>Briganti, Alberto</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130601</creationdate><title>Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis</title><author>Abdollah, Firas ; Suardi, Nazareno ; Cozzarini, Cesare ; Gallina, Andrea ; Capitanio, Umberto ; Bianchi, Marco ; Sun, Maxine ; Fossati, Nicola ; Passoni, Niccolò Maria ; Fiorino, Claudio ; Di Muzio, Nadia ; Karakiewicz, Pierre I ; Rigatti, Patrizio ; Montorsi, Francesco ; Briganti, Alberto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-78020b6d4fbf1dbf192b3b1536c3211b12885a077eff9745583f7fbed86142e43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adjuvant</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Cohort Studies</topic><topic>Combined Modality Therapy</topic><topic>Disease-Free Survival</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Lymph Node Excision</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Grading</topic><topic>Neoplasm recurrence</topic><topic>Neoplasm Staging</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Patient Selection</topic><topic>Pelvis</topic><topic>Proportional Hazards Models</topic><topic>Prostatectomy</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Prostatic neoplasms/surgery</topic><topic>Radiotherapy</topic><topic>Radiotherapy, Adjuvant</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Risk factors</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdollah, Firas</creatorcontrib><creatorcontrib>Suardi, Nazareno</creatorcontrib><creatorcontrib>Cozzarini, Cesare</creatorcontrib><creatorcontrib>Gallina, Andrea</creatorcontrib><creatorcontrib>Capitanio, Umberto</creatorcontrib><creatorcontrib>Bianchi, Marco</creatorcontrib><creatorcontrib>Sun, Maxine</creatorcontrib><creatorcontrib>Fossati, Nicola</creatorcontrib><creatorcontrib>Passoni, Niccolò Maria</creatorcontrib><creatorcontrib>Fiorino, Claudio</creatorcontrib><creatorcontrib>Di Muzio, Nadia</creatorcontrib><creatorcontrib>Karakiewicz, Pierre I</creatorcontrib><creatorcontrib>Rigatti, Patrizio</creatorcontrib><creatorcontrib>Montorsi, Francesco</creatorcontrib><creatorcontrib>Briganti, Alberto</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdollah, Firas</au><au>Suardi, Nazareno</au><au>Cozzarini, Cesare</au><au>Gallina, Andrea</au><au>Capitanio, Umberto</au><au>Bianchi, Marco</au><au>Sun, Maxine</au><au>Fossati, Nicola</au><au>Passoni, Niccolò Maria</au><au>Fiorino, Claudio</au><au>Di Muzio, Nadia</au><au>Karakiewicz, Pierre I</au><au>Rigatti, Patrizio</au><au>Montorsi, Francesco</au><au>Briganti, Alberto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis</atitle><jtitle>European urology</jtitle><addtitle>Eur Urol</addtitle><date>2013-06-01</date><risdate>2013</risdate><volume>63</volume><issue>6</issue><spage>998</spage><epage>1008</epage><pages>998-1008</pages><issn>0302-2838</issn><eissn>1873-7560</eissn><coden>EUURAV</coden><abstract>Abstract Background The role of adjuvant radiotherapy (ART) after radical prostatectomy (RP) on survival of patients with prostate cancer (PCa) is still controversial. Objective We tested the impact of ART on cancer-specific mortality (CSM) and overall mortality (OM) in PCa patients according to pathologic PCa features. Design, setting, and participants We evaluated 1049 PCa patients treated with RP and extended pelvic lymph node dissection alone or in combination with adjuvant treatments between 1998 and 2008. All patients had positive surgical margins and/or pT3/pT4 disease with or without positive lymph nodes. Outcome measurements and statistical analysis Cox regression analyses tested the relationship between pathologic characteristics and CSM rates. Independent predictors of survival were used to develop a novel risk score based on the number of risk factors. Finally, Cox regression models tested the relationship between ART and survival according to the number of risk factors. Results and limitations On multivariable analyses, only pathologic Gleason score ≥8, pT3b/T4 stage, and presence of positive lymph nodes represented independent predictors of CSM (all p ≤ 0.02). The cumulative number of these pathologic findings was used to develop a risk score, which was 0, 1, 2, and 3 in 43.6%, 22.1%, 20.7%, and 13.6% of patients, respectively. In patients sharing more than two mentioned predictors of CSM (primarily having a risk score of 0 or 1), ART did not significantly improve survival (all p ≥ 0.4). Conversely, in patients with a risk score ≥2, ART was associated with lower CSM and OM rates (all p = 0.006). The observational nature of the cohort represents a limitation of the study. Conclusions ART significantly improved survival only in patients with at least two of the following pathologic features at RP: Gleason score ≥8, pT3/pT4 disease, and positive lymph nodes. These patients represent the ideal candidates for ART after RP.</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>23122664</pmid><doi>10.1016/j.eururo.2012.10.036</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0302-2838 |
ispartof | European urology, 2013-06, Vol.63 (6), p.998-1008 |
issn | 0302-2838 1873-7560 |
language | eng |
recordid | cdi_proquest_miscellaneous_1345513402 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Adjuvant Adult Aged Aged, 80 and over Biological and medical sciences Cohort Studies Combined Modality Therapy Disease-Free Survival Gynecology. Andrology. Obstetrics Humans Lymph Node Excision Male Male genital diseases Medical sciences Middle Aged Multivariate Analysis Neoplasm Grading Neoplasm recurrence Neoplasm Staging Nephrology. Urinary tract diseases Patient Selection Pelvis Proportional Hazards Models Prostatectomy Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Prostatic Neoplasms - therapy Prostatic neoplasms/surgery Radiotherapy Radiotherapy, Adjuvant Retrospective Studies Risk Assessment Risk factors Survival Analysis Treatment Outcome Tumors Tumors of the urinary system Urinary tract. Prostate gland Urology |
title | Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T09%3A19%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Selecting%20the%20Optimal%20Candidate%20for%20Adjuvant%20Radiotherapy%20After%20Radical%20Prostatectomy%20for%20Prostate%20Cancer:%20A%20Long-term%20Survival%20Analysis&rft.jtitle=European%20urology&rft.au=Abdollah,%20Firas&rft.date=2013-06-01&rft.volume=63&rft.issue=6&rft.spage=998&rft.epage=1008&rft.pages=998-1008&rft.issn=0302-2838&rft.eissn=1873-7560&rft.coden=EUURAV&rft_id=info:doi/10.1016/j.eururo.2012.10.036&rft_dat=%3Cproquest_cross%3E1345513402%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1345513402&rft_id=info:pmid/23122664&rft_els_id=1_s2_0_S0302283812012675&rfr_iscdi=true |